Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 79,000 shares, a growth of 101.5% from the March 31st total of 39,200 shares. Currently, 2.2% of the company’s stock are sold short. Based on an average trading volume of 206,900 shares, the short-interest ratio is presently 0.4 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Galmed Pharmaceuticals in a research note on Wednesday. They set a “sell” rating for the company.

Galmed Pharmaceuticals Stock Performance

NASDAQ:GLMD remained flat at $0.39 during trading hours on Friday. The company’s stock had a trading volume of 27,223 shares, compared to its average volume of 260,258. Galmed Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $7.80. The firm has a market cap of $1.98 million, a P/E ratio of -0.12 and a beta of 0.87. The business’s 50 day simple moving average is $0.36 and its 200-day simple moving average is $0.38.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.